 The principle objectives of this study are to assess safety and tolerability and to explore pharmacokineticPK and pharmacodynamicPD parameters of a single dose of a novel very-long acting insulin formulation HM12460A in comparison to a single dose of human Neutral Protamine Hagedorn NPH in healthy volunteers part 1, subjects with type 1 diabetes part 2 and in subjects with type 2 diabetes part 3. 